Journal of Lipid Research, Vol 34, 279-294, Copyright © 1993 by Lipid Research, Inc.

ARTICLES

In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT

BR Krause, M Anderson, CL Bisgaier, T Bocan, R Bousley, P DeHart, A Essenburg, K Hamelehle, R Homan and K Kieft
Department of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105.

CI-976, a new trimethoxy fatty acid anilide, is a potent and specific inhibitor of liver and intestinal acyl coenzyme A:cholesterol acyltransferase (ACAT) in vitro. Several in vivo approaches were used to determine the efficacy and sites of action of this compound in rats. CI-976 decreased non-high density lipoprotein (HDL)-cholesterol and increased HDL-cholesterol in rats with pre-established dyslipidemia. High performance gel chromatographic separation of plasma lipoproteins also revealed that CI-976, but not CL 277,082, lowered low density lipoprotein (LDL)-cholesterol and elevated HDL-cholesterol. Bay o 2752, octimibate, melinamide, and SaH 58-035 were all less potent in vivo compared to CI-976 and CL 277,082, and CI-976 produced the greatest decrease in liver cholesteryl esters. Subcutaneous (SC) administration of CI-976 was also efficacious in cholesterol-fed animals. In sucrose- fed rats, oral and SC CI-976 administration potently lowered plasma triglycerides. Hepatic cholesteryl ester accumulation in the ethinyl estradiol-treated rat was also diminished by orally administered CI- 976. ACAT activity and cholesteryl ester mass were dose-dependently decreased in the livers from cholesterol-fed rats treated with CI-976, suggesting a direct effect on the liver. In both hypercholesterolemic and hypertriglyceridemic models, CI-976 also decreased plasma apoB concentrations. In other experiments radiolabeled CI-976 accumulated in the liver after multiple doses. Time-dependent changes in biliary lipid and bile acid secretion suggested that free cholesterol did not accumulate in the liver but instead was excreted as such or as bile acid. Finally, inhibition of endogenous and exogenous intestinal cholesterol absorption was demonstrated using several in vivo techniques. The combined data strongly supports the hypothesis that orally administered CI-976 inhibits both intestinal and hepatic ACAT, and that both of these enzymes may be determinants of plasma lipid concentrations in the rat.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Y. Fujiwara, N. Kiyota, M. Hori, S. Matsushita, Y. Iijima, K. Aoki, D. Shibata, M. Takeya, T. Ikeda, T. Nohara, et al. Esculeogenin A, a New Tomato Sapogenol, Ameliorates Hyperlipidemia and Atherosclerosis in ApoE-Deficient Mice by Inhibiting ACAT Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2400 - 2406. [Abstract] [Full Text] [PDF]

				K. V. Batt, M. Avella, E. H. Moore, B. Jackson, K. E. Suckling, and K. M. Botham Differential Effects of Low-Density Lipoprotein and Chylomicron Remnants on Lipid Accumulation in Human Macrophages Experimental Biology and Medicine, June 1, 2004; 229(6): 528 - 537. [Abstract] [Full Text] [PDF]

				D. E. Telford, J. Y. Edwards, S. M. Lipson, B. Sutherland, P. H. R. Barrett, J. R. Burnett, E. S. Krul, B. T. Keller, and M. W. Huff Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB J. Lipid Res., May 1, 2003; 44(5): 943 - 952. [Abstract] [Full Text] [PDF]

				K. Aragane, K. Fujinami, K. Kojima, and J. Kusunoki ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits J. Lipid Res., April 1, 2001; 42(4): 480 - 488. [Abstract] [Full Text]

				D. G. Robertson, M. A. Breider, and M. A. Milad Preclinical Safety Evaluation of Avasimibe in Beagle Dogs: An ACAT Inhibitor with Minimal Adrenal Effects Toxicol. Sci., February 1, 2001; 59(2): 324 - 334. [Abstract] [Full Text] [PDF]

				J. R. Burnett, L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs J. Lipid Res., July 1, 1999; 40(7): 1317 - 1328. [Abstract] [Full Text]

				L. J. Wilcox, P. H. R. Barrett, R. S. Newton, and M. W. Huff ApoB100 Secretion From HepG2 Cells is Decreased by the ACAT Inhibitor CI-1011 : An Effect Associated With Enhanced Intracellular Degradation of ApoB Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 939 - 949. [Abstract] [Full Text] [PDF]

				J.-L. Escary, H. A. Choy, K. Reue, X.-P. Wang, L. W. Castellani, C. K. Glass, A. J. Lusis, and M. C. Schotz Paradoxical effect on atherosclerosis of hormone-sensitive lipase overexpression in macrophages J. Lipid Res., March 1, 1999; 40(3): 397 - 404. [Abstract] [Full Text]

				I. Ishii, N. Yokoyama, M. Yanagimachi, N. Ashikawa, M. Hata, S. Murakami, Y. Asami, N. Morisaki, Y. Saito, S. Ohmori, et al. Stimulation of Cholesterol Release from Rabbit Foam Cells by the Action of a New Inhibitor for Acyl CoA:Cholesterol Acyltransferase (ACAT), HL-004 J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 115 - 121. [Abstract] [Full Text]

				R. Homan and K. L. Hamelehle Phospholipase A2 relieves phosphatidylcholine inhibition of micellar cholesterol absorption and transport by human intestinal cell line Caco-21 J. Lipid Res., June 1, 1998; 39(6): 1197 - 1209. [Abstract] [Full Text]

				J.-L. Escary, H. A. Choy, K. Reue, and M. C. Schotz Hormone-Sensitive Lipase Overexpression Increases Cholesteryl Ester Hydrolysis in Macrophage Foam Cells Arterioscler. Thromb. Vasc. Biol., June 1, 1998; 18(6): 991 - 998. [Abstract] [Full Text] [PDF]

				C. P. Carter, P. N. Howles, and D. Y. Hui Genetic Variation in Cholesterol Absorption Efficiency among Inbred Strains of Mice J. Nutr., July 1, 1997; 127(7): 1344 - 1348. [Abstract] [Full Text]

				M. W. Sinz, A. E. Black, S. M. Bjorge, A. Holmes, B. K. Trivedi, and T. F. Woolf In Vitro and In Vivo Disposition of 2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide (CI-976). Identification of a Novel Five-Carbon Cleavage Metabolite in Rats Drug Metab. Dispos., January 1, 1997; 25(1): 123 - 130. [Abstract] [Full Text]

				I.J. Martins, B.-C. Mortimer, and T.G. Redgrave Effect of the ACAT Inhibitor CL 277,082 on Apolipoprotein B48 Transport in Mesenteric Lymph and on Plasma Clearance of Chylomicrons and Remnants Arterioscler. Thromb. Vasc. Biol., January 1, 1997; 17(1): 211 - 216. [Abstract] [Full Text]

				P. N. Howles, C. P. Carter, and D. Y. Hui Dietary Free and Esterified Cholesterol Absorption in Cholesterol Esterase (Bile Salt-stimulated Lipase) Gene-targeted Mice J. Biol. Chem., March 22, 1996; 271(12): 7196 - 7202. [Abstract] [Full Text] [PDF]

				P. J. Uelmen, K. Oka, M. Sullivan, C. C. Y. Chang, T. Y. Chang, and L. Chan Tissue-specific Expression and Cholesterol Regulation of Acylcoenzyme A:Cholesterol Acyltransferase (ACAT) in Mice J. Biol. Chem., November 3, 1995; 270(44): 26192 - 26201. [Abstract] [Full Text] [PDF]

				C. C. Y. Chang, N. Sakashita, K. Ornvold, O. Lee, E. T. Chang, R. Dong, S. Lin, C.-Y. G. Lee, S. C. Strom, R. Kashyap, et al. Immunological Quantitation and Localization of ACAT-1 and ACAT-2 in Human Liver and Small Intestine J. Biol. Chem., September 1, 2000; 275(36): 28083 - 28092. [Abstract] [Full Text] [PDF]